tiprankstipranks
Advertisement
Advertisement

EDIT Stock Latest News

Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI
The FlyEditas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI
6d ago
EDIT
TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’
PremiumThe Fly
TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’
6d ago
EDIT
Editas Medicine Raises Capital Through Public Equity Offering
PremiumCompany Announcements
Editas Medicine Raises Capital Through Public Equity Offering
7d ago
8K
EDIT
Editas Medicine 55.6M share Secondary priced at $2.25
PremiumThe Fly
Editas Medicine 55.6M share Secondary priced at $2.25
8d ago
EDIT
Editas Medicine Suspends Existing At-The-Market Offering Prospectus
PremiumCompany Announcements
Editas Medicine Suspends Existing At-The-Market Offering Prospectus
8d ago
8K
EDIT
Editas Medicine announces common stock, warrant offering, no amount given
PremiumThe FlyEditas Medicine announces common stock, warrant offering, no amount given
8d ago
EDIT
Editas Showcases Promising EDIT-401 Data for Hyperlipidemia
Premium
Company Announcements
Editas Showcases Promising EDIT-401 Data for Hyperlipidemia
8d ago
8K
EDIT
Analyst Maintains Buy on Editas Medicine, Reiterates $5 Price Target on EDIT-401 Progress and Strong Cash Runway
Premium
Ratings
Analyst Maintains Buy on Editas Medicine, Reiterates $5 Price Target on EDIT-401 Progress and Strong Cash Runway
8d ago
EDIT
Editas Medicine presented preclinical data for EDIT-401 at EAS Congress
PremiumThe Fly
Editas Medicine presented preclinical data for EDIT-401 at EAS Congress
8d ago
EDIT
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data
PremiumCompany Announcements
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data
20d ago
8K
EDIT
Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia
PremiumThe Fly
Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia
20d ago
EDIT
FDA Commissioner Marty Makary resigns
PremiumThe Fly
FDA Commissioner Marty Makary resigns
21d ago
AZN
BMY
Analyst Phil Nadeau Reiterates Buy on Editas Medicine, Citing Promising EDIT-401 Data, Strong Cash Runway, and Large Untapped HeFH Opportunity
PremiumRatingsAnalyst Phil Nadeau Reiterates Buy on Editas Medicine, Citing Promising EDIT-401 Data, Strong Cash Runway, and Large Untapped HeFH Opportunity
28d ago
EDIT
Editas Medicine reports Q1 EPS (26c), consensus (24c)
Premium
The Fly
Editas Medicine reports Q1 EPS (26c), consensus (24c)
29d ago
EDIT
EDIT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
EDIT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
30d ago
EDIT
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
PremiumThe Fly
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
1M ago
BA
BE
Editas Medicine price target raised to $15 from $13 at Evercore ISI
PremiumThe Fly
Editas Medicine price target raised to $15 from $13 at Evercore ISI
2M ago
EDIT
USPTO Ruling Impacts Editas Medicine CRISPR IP Position
PremiumCompany Announcements
USPTO Ruling Impacts Editas Medicine CRISPR IP Position
2M ago
8K
EDIT
Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents
PremiumThe Fly
Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents
2M ago
EDIT
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects
PremiumCompany AnnouncementsRegulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects
3M ago
EDIT
Editas Medicine upgraded to Buy from Hold at JonesResearch
Premium
The Fly
Editas Medicine upgraded to Buy from Hold at JonesResearch
3M ago
EDIT
Editas Medicine reports Q4 EPS (6c), consensus (26c)
Premium
The Fly
Editas Medicine reports Q4 EPS (6c), consensus (26c)
3M ago
EDIT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >